IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock Position Increased by Nordea Investment Management AB

Nordea Investment Management AB boosted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXXFree Report) by 15.5% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 13,719 shares of the company’s stock after purchasing an additional 1,839 shares during the quarter. Nordea Investment Management AB’s holdings in IDEXX Laboratories were worth $7,447,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Valley National Advisers Inc. increased its stake in IDEXX Laboratories by 84.6% during the 4th quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock valued at $26,000 after buying an additional 22 shares during the period. Riverview Trust Co acquired a new position in IDEXX Laboratories during the 1st quarter valued at about $26,000. DSM Capital Partners LLC acquired a new position in IDEXX Laboratories during the 4th quarter valued at about $33,000. Private Wealth Management Group LLC acquired a new position in IDEXX Laboratories during the 4th quarter valued at about $34,000. Finally, Venturi Wealth Management LLC increased its stake in IDEXX Laboratories by 226.3% during the 4th quarter. Venturi Wealth Management LLC now owns 62 shares of the company’s stock valued at $34,000 after buying an additional 43 shares during the period. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Trading Down 0.5 %

Shares of NASDAQ IDXX opened at $483.73 on Tuesday. The firm has a market capitalization of $39.95 billion, a PE ratio of 46.83, a PEG ratio of 3.96 and a beta of 1.32. IDEXX Laboratories, Inc. has a one year low of $372.50 and a one year high of $583.39. The company has a current ratio of 1.57, a quick ratio of 1.16 and a debt-to-equity ratio of 0.40. The business has a 50-day moving average price of $499.92 and a two-hundred day moving average price of $523.81.

IDEXX Laboratories (NASDAQ:IDXXGet Free Report) last announced its quarterly earnings data on Wednesday, May 1st. The company reported $2.81 EPS for the quarter, beating analysts’ consensus estimates of $2.68 by $0.13. The firm had revenue of $964.10 million for the quarter, compared to the consensus estimate of $965.43 million. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. As a group, analysts predict that IDEXX Laboratories, Inc. will post 11.03 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have weighed in on IDXX. Stifel Nicolaus cut their price target on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a report on Monday, June 24th. Barclays decreased their price target on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a research report on Thursday, May 2nd. StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Friday, June 14th. Morgan Stanley decreased their target price on IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating on the stock in a report on Tuesday, May 14th. Finally, William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, IDEXX Laboratories has a consensus rating of “Moderate Buy” and an average target price of $586.63.

View Our Latest Stock Report on IDEXX Laboratories

Insider Buying and Selling

In other IDEXX Laboratories news, Director Bruce L. Claflin sold 200 shares of the business’s stock in a transaction dated Friday, May 17th. The stock was sold at an average price of $540.80, for a total value of $108,160.00. Following the transaction, the director now owns 161 shares in the company, valued at $87,068.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 2.18% of the stock is owned by corporate insiders.

IDEXX Laboratories Profile

(Free Report)

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

See Also

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXXFree Report).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.